Literature DB >> 23118228

LUZ-Y, a novel platform for the mammalian cell production of full-length IgG-bispecific antibodies.

Bernd J Wranik1, Erin L Christensen, Gabriele Schaefer, Janet K Jackman, Andrew C Vendel, Dan Eaton.   

Abstract

The ability of bispecific antibodies to simultaneously bind two unique antigens has great clinical potential. However, most approaches utilized to generate bispecific antibodies yield antibody-like structures that diverge significantly from the structure of archetype human IgG, and those that do approach structural similarity to native antibodies are often challenging to engineer and manufacture. Here, we present a novel platform for the mammalian cell production of bispecific antibodies that differ from their parental mAbs by only a single point mutation per heavy chain. Central to this platform is the addition of a leucine zipper to the C terminus of the C(H)3 domain of the antibody that is sufficient to drive the heterodimeric assembly of antibody heavy chains and can be readily removed post-purification. Using this approach, we developed various antibody constructs including one-armed Abs, bispecific antibodies that utilize a common light chain, and bispecific antibodies that pair light chains to their cognate heavy chains via peptide tethers. We have applied this technology to various antibody pairings and will demonstrate the engineering, purification, and biological activity of these antibodies herein.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23118228      PMCID: PMC3527920          DOI: 10.1074/jbc.M112.397869

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies.

Authors:  Jonathan H Davis; Christel Aperlo; Yue Li; Emmi Kurosawa; Yan Lan; Kin-Ming Lo; James S Huston
Journal:  Protein Eng Des Sel       Date:  2010-02-04       Impact factor: 1.650

2.  'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization.

Authors:  J B Ridgway; L G Presta; P Carter
Journal:  Protein Eng       Date:  1996-07

3.  An efficient route to human bispecific IgG.

Authors:  A M Merchant; Z Zhu; J Q Yuan; A Goddard; C W Adams; L G Presta; P Carter
Journal:  Nat Biotechnol       Date:  1998-07       Impact factor: 54.908

4.  Hybrid antibodies can target sites for attack by T cells.

Authors:  U D Staerz; O Kanagawa; M J Bevan
Journal:  Nature       Date:  1985 Apr 18-24       Impact factor: 49.962

5.  p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.

Authors:  R M Hudziak; G D Lewis; M Winget; B M Fendly; H M Shepard; A Ullrich
Journal:  Mol Cell Biol       Date:  1989-03       Impact factor: 4.272

6.  Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site.

Authors:  Jenny Bostrom; Shang-Fan Yu; David Kan; Brent A Appleton; Chingwei V Lee; Karen Billeci; Wenyan Man; Franklin Peale; Sarajane Ross; Christian Wiesmann; Germaine Fuh
Journal:  Science       Date:  2009-03-20       Impact factor: 47.728

7.  Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling.

Authors:  Janet Jackman; Yongmei Chen; Arthur Huang; Barbara Moffat; Justin M Scheer; Steven R Leong; Wyne P Lee; Juan Zhang; Navneet Sharma; Yanmei Lu; Suhasini Iyer; Robert L Shields; Nancy Chiang; Michele C Bauer; Diana Wadley; Merone Roose-Girma; Richard Vandlen; Daniel G Yansura; Yan Wu; Lawren C Wu
Journal:  J Biol Chem       Date:  2010-05-05       Impact factor: 5.157

8.  Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression.

Authors:  Gabriele Schaefer; Lihua Shao; Klara Totpal; Robert W Akita
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

9.  Formation of a bispecific antibody by the use of leucine zippers.

Authors:  S A Kostelny; M S Cole; J Y Tso
Journal:  J Immunol       Date:  1992-03-01       Impact factor: 5.422

Review 10.  Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture.

Authors:  R J Harris
Journal:  J Chromatogr A       Date:  1995-06-23       Impact factor: 4.759

View more
  13 in total

1.  Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines.

Authors:  Christoph Spiess; Jack Bevers; Janet Jackman; Nancy Chiang; Gerald Nakamura; Michael Dillon; Hongbin Liu; Patricia Molina; J Michael Elliott; Whitney Shatz; Justin M Scheer; Glen Giese; Josefine Persson; Yin Zhang; Mark S Dennis; James Giulianotti; Prateek Gupta; Dorothea Reilly; Enzo Palma; Jianyong Wang; Eric Stefanich; Heleen Scheerens; Germaine Fuh; Lawren C Wu
Journal:  J Biol Chem       Date:  2013-07-23       Impact factor: 5.157

2.  Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design.

Authors:  Thomas Spreter Von Kreudenstein; Eric Escobar-Carbrera; Paula I Lario; Igor D'Angelo; Karine Brault; John Kelly; Yves Durocher; Jason Baardsnes; R Jeremy Woods; Michael Hongwei Xie; Pierre-Alain Girod; Michael D L Suits; Martin J Boulanger; David K Y Poon; Gordon Y K Ng; Surjit B Dixit
Journal:  MAbs       Date:  2013-07-08       Impact factor: 5.857

3.  Purification of common light chain IgG-like bispecific antibodies using highly linear pH gradients.

Authors:  Beth Sharkey; Sarat Pudi; Ian Wallace Moyer; Lihui Zhong; Bianka Prinz; Hemanta Baruah; Heather Lynaugh; Sampath Kumar; K Dane Wittrup; Juergen H Nett
Journal:  MAbs       Date:  2016-12-12       Impact factor: 5.857

4.  An efficient route to bispecific antibody production using single-reactor mammalian co-culture.

Authors:  Whitney Shatz; Domingos Ng; George Dutina; Athena W Wong; Diana Ronai Dunshee; Junichiro Sonoda; Amy Shen; Justin M Scheer
Journal:  MAbs       Date:  2016 Nov/Dec       Impact factor: 5.857

Review 5.  Recombinant antibodies aggregation and overcoming strategies in CHO cells.

Authors:  Tingting Xu; Jihong Zhang; Tianyun Wang; Xiaoyin Wang
Journal:  Appl Microbiol Biotechnol       Date:  2022-05-24       Impact factor: 4.813

6.  Improving target cell specificity using a novel monovalent bispecific IgG design.

Authors:  Yariv Mazor; Vaheh Oganesyan; Chunning Yang; Anna Hansen; Jihong Wang; Hongji Liu; Kris Sachsenmeier; Marcia Carlson; Dhanesh V Gadre; Martin Jack Borrok; Xiang-Qing Yu; William Dall'Acqua; Herren Wu; Partha Sarathi Chowdhury
Journal:  MAbs       Date:  2015       Impact factor: 5.857

7.  Balancing the Expression and Production of a Heterodimeric Protein: Recombinant Agkisacutacin as a Novel Antithrombotic Drug Candidate.

Authors:  Yugang Guo; Jing Wu; Hao Jia; Wei Chen; Changsheng Shao; Lei Zhao; Jiajia Ma; Rui Li; Yongjun Zhong; Fang Fang; Dong Wang; Jie Sun; Fang Qian; Xiangrong Dai; Guohui Zhang; Zhigang Tian; Benjamin Xiaoyi Li; Weihua Xiao
Journal:  Sci Rep       Date:  2015-07-06       Impact factor: 4.379

Review 8.  The making of bispecific antibodies.

Authors:  Ulrich Brinkmann; Roland E Kontermann
Journal:  MAbs       Date:  2017 Feb/Mar       Impact factor: 5.857

Review 9.  Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.

Authors:  Hongyan Liu; Abhishek Saxena; Sachdev S Sidhu; Donghui Wu
Journal:  Front Immunol       Date:  2017-01-26       Impact factor: 7.561

10.  Tethered-variable CL bispecific IgG: an antibody platform for rapid bispecific antibody screening.

Authors:  Hok Seon Kim; Diana Ronai Dunshee; Angie Yee; Raymond K Tong; Ingrid Kim; Farzam Farahi; Jo-Anne Hongo; James A Ernst; Junichiro Sonoda; Christoph Spiess
Journal:  Protein Eng Des Sel       Date:  2017-09-01       Impact factor: 1.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.